Effects of dynamic contrast enhancement on transition zone prostate cancer in Prostate Imaging Reporting and Data System Version 2.1
By: Jiahui Zhang, Lili Xu, Gumuyang Zhang, Xiaoxiao Zhang, Xin Bai, Hao Sun and Zhengyu Jin
References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21660
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71: 7-33. doi: 10.3322/caac.21654
- Teoh J, Hirai H W, Ho J, Chan F, Tsoi K, Ng C. Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS One 2019; 14: e221775. doi: 10.1371/journal.pone.0221775
- Turkbey B, Brown AM, Sankineni S, Wood BJ, Pinto PA, Choyke PL. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA Cancer J Clin 2016; 66: 326-36. doi: 10.3322/caac.21333
- Ueno Y, Tamada T, Bist V, Reinhold C, Miyake H, Tanaka U, et al. Multiparametric magnetic resonance imaging: current role in prostate cancer management. Int J Urol 2016; 23: 550-7. doi: 10.1111/iju.13119
- Litjens G, Elliott R, Shih N, Feldman M, Kobus T, Kaa C, et al. Computer-extracted features can distinguish noncancerous confounding disease from prostatic adenocarcinoma at multiparametric MR imaging. Radiology 2016; 278: 135-45. doi: 10.1148/radiol.201514285
- Remmers S, Roobol M J. Personalized strategies in population screening for prostate cancer. Int J Cancer 2020; 147: 2977-87. doi: 10.1002/ijc.33045
- Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-57. doi: 10.1007/s00330-011-2377-y. 9
- Gupta RT, Mehta KA, Turkbey B, Verma S. PI-RADS: past, present, and future. J Magn Reson Imaging 2020; 52: 33-53. doi: 10.1002/jmri.26896
- Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019; 76: 340-51. doi: 10.1016/j.eururo.2019.02.033
- Gatti M, Faletti R, Calleris G, Giglio J, Berzovini C, Gentile F, et al. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdom Radiol 2019; 44: 1883-93. doi: 10.1007/ s00261-019-01934-3
- Wassberg C, Akin O, Vargas HA, Dave AS, Zhang Jb, Hricak H. The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol 2012; 199: 360-6. doi: 10.2214/ AJR.11.6923
- Tamada T, Sone T, Jo Y, Hiratsuka J, Higaki A, Higashi H, et al. Locally recurrent prostate cancer after high- dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2- weighted imaging in localizing tumors. AJR Am J Roentgenol 2011; 197: 408-14. doi: 10.2214/AJR.10.5772
- Kuhl CK, Bruhn R, Krämer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology 2017; 285: 493-505. doi: 10.1148/ radiol.2017170129
- Junker D, Steinkohl F, Fritz V, Bektic J, Tokas T, Aigner F, et al. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations? World J Urol 2019; 37: 691-9. doi: 10.1007/s00345-018-2428-y
- Di Campli E, Delli P A, Seccia B, Cianci R, d’Annibale M, Colasante A, et al. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: comparison between readers with different experience. Eur J Radiol 2018; 101: 17-23. doi: 10.1016/j.ejrad.2018.01.028
- Huebner NA, Korn S, Resch I, Grubmüller B, Gross T, Gale R, et al. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media? Eur Radiol 2021; 31: 3754-64. doi: 10.1007/s00330-020-07494-1
- Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2017; 41: e1-7. doi: 10.1097/PAS.0000000000000820
- Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016; 69: 16-40. doi: 10.1016/j.eururo.2015.08.05
- Oishi M, Shin T, Ohe C, Nassiri N, Palmer SL, Aron M, et al. Which patients with negative magnetic resonance imaging can safely avoid biopsy for prostate cancer? J Urol 2019; 201: 268-76. doi: 10.1016/j.juro.2018.08.046
- Tamada T, Kido A, Yamamoto A, Takeuchi M, Miyaji Y, Moriya T, et al. Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2.1. J Magn Reson Imaging 2021; 53: 283-91. doi: 10.1002/jmri.27283
- Taghipour M, Ziaei A, Alessandrino F, Hassanzadeh E, Harisinghani M, Vangel M, et al. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdom Radiol 2019; 44: 1520-7. doi: 10.1007/s00261-018-1807-6
- Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-54. doi: 10.1148/ radiol.2291020200
- Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem 2004; 91: 125- 50. doi: 10.1002/jcb.10772
- Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, et al. Overview of dynamic contrast- enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol 2012; 198: 1277-88. doi: 10.2214/ AJR.12.8510
- Sanz-Requena R, Martí-Bonmatí L, Pérez-Martínez R, García-Martí G. Dynamic contrast-enhanced case- control analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness. Eur J Radiol 2016; 85: 2119-26. doi: 10.1016/j.ejrad.2016.09.022
Language: English
Page range: 42 - 50
Submitted on: Oct 9, 2022
Accepted on: Nov 18, 2022
Published on: Jan 20, 2023
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2023 Jiahui Zhang, Lili Xu, Gumuyang Zhang, Xiaoxiao Zhang, Xin Bai, Hao Sun, Zhengyu Jin, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.